Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Neurology & CNS · Phase I

Neurology & CNS programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs 138

Quick answer

Neurology & CNS Phase I programs: NovaPharmaNews indexes 138 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Pipeline programs

Page 1 of 3

  1. 14-XC-CL

    Lacuna Pharma Pty Ltd

    Parkinson’s Disease

    phase 1 other active

    1 trial

  2. 300 mg [C14] CT1812

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  3. 3135003

    Orion Laboratories Pty.

    Parkinson desease

    phase 1 other active

    1 trial

  4. 3135004

    Orion Laboratories Pty.

    Parkinson disease

    phase 1 other active

    1 trial

  5. 50mg Ezogabine/retigabine

    GlaxoSmithKline

    Epilepsy

    phase 1 small molecule completed

    1 trial

  6. 63733657EDI1003

    Janssen-Cilag International N.V.

    Alzheimer's Disease (Healthy Participants)

    phase 1 other active

    1 trial

  7. A Multiple-Ascending-Dose Study of MK-1708 in Healthy Participants

    Merck Sharp and Dohme

    Amyotrophic lateral sclerosis and Alzheimer’s disease

    phase 1 other active

    1 trial

  8. A randomised for Depression, Cognitive dysfuncti…

    Lacuna Pharma Pty Ltd

    Depression, Cognitive dysfunction, Alzheimer’s disease

    phase 1 other active

    1 trial

  9. A study to find out how healthy people tolerate a new drug called S221237.

    The George Institute

    Parkinson disease (PD)

    phase 1 other active

    1 trial

  10. ACTOS (Pioglitazone)

    Takeda

    Multiple Sclerosis, Relapsing-Remitting

    phase 1 small molecule completed

    1 trial

  11. ACU193

    Acumen Pharmaceuticals

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  12. ALN-5288

    Alnylam Netherlands B.V.

    Alzheimer's Disease

    phase 1 small molecule active

    1 trial

  13. ALN-5288-001

    Alnylam Netherlands B.V.

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  14. ALN-APP

    Alnylam Netherlands B.V.

    Early-Onset Alzheimer Disease

    phase 1 small molecule active

    1 trial

  15. ALN-APP-001

    Alnylam Netherlands B.V.

    Early-onset Alzheimer's disease (EOAD)

    phase 1 other active

    1 trial

  16. ALN-SNCA

    Regeneron UK Limited

    Parkinsons Disease

    phase 1 small molecule active

    1 trial

  17. ALN-SNCA-PD-2482

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 1 other active

    1 trial

  18. AUTO1-MS1

    Autolus GmbH

    Refractory Progressive Multiple Sclerosis

    phase 1 other active

    1 trial

  19. BIA-28-6156-111

    Bial Portela & Companhia S.A.

    Parkinson's disease

    phase 1 other active

    1 trial

  20. BIIB094

    IONIS PHARMACEUTICALS INC

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  21. BIS-001 ER

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy, Complex Partial

    phase 1 small molecule completed

    1 trial

  22. BN44083

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  23. BP42230

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  24. BP45211

    Hoffmann-La Roche

    Alzheimer’s Disease (AD)

    phase 1 other active

    1 trial

  25. BP45361

    Hoffmann-La Roche

    Parkinson’s Disease

    phase 1 other active

    1 trial

  26. BRIVA-10-24

    Lacuna Pharma Pty Ltd

    Epilepsy

    phase 1 other active

    1 trial

  27. BXCL501 80 Micrograms

    BioXcel Therapeutics

    Schizophrenia

    phase 1 small molecule active

    1 trial

  28. Bioequivalence of Cladribine 10 mg from two different products

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers. The intended indication is for treatment of adult patients with highly active relapsing multiple sclerosis (MS).

    phase 1 other active

    1 trial

  29. CA061-1006

    Celgene Europe Limited

    Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS)

    phase 1 other active

    1 trial

  30. CDLX313A12101

    Novartis Pharmaceuticals

    Parkinson’s Disease

    phase 1 other active

    1 trial

  31. CERE-110: Adeno-Associated Virus Delivery of NGF

    SANGAMO THERAPEUTICS, INC

    Alzheimer's Disease

    phase 1 gene therapy completed

    1 trial

  32. CERE-120: AAV2-NTN

    SANGAMO THERAPEUTICS, INC

    Parkinson's Disease

    phase 1 gene therapy completed

    1 trial

  33. CN0140003

    Bristol-Myers Squibb Australia Pty Ltd

    Neuropsychiatric indications and potentially other conditions

    phase 1 other active

    1 trial

  34. CNCT19 cell injection

    Juventas Cell Therapy

    Neurological Autoimmune Diseases

    phase 1 mab active

    1 trial

  35. Carbidopa

    United Therapeutics Europe Ltd

    Multiple Sclerosis

    phase 1 small molecule completed

    1 trial

  36. Characterization of Immune Response in Participants from a Posdinemab Study

    Janssen-Cilag International N.V.

    Early Alzheimer's disease

    phase 1 other active

    1 trial

  37. Citalopram

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Depression

    phase 1 small molecule active

    1 trial

  38. DNL201

    Denali Therapeutics

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  39. DNL628

    Denali Therapeutics

    Alzheimer Disease, Early Onset

    phase 1 small molecule active

    1 trial

  40. DNL747

    Denali Therapeutics

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  41. DNLI-K-0001

    Denali Therapeutics

    Early Alzheimer's Disease

    phase 1 other active

    1 trial

  42. Divalproex Sodium Extended-release 250mg

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 1 small molecule active

    1 trial

  43. Donepezil Dihydroxynaphthalate for Injection

    Shanghai University of Traditional Chinese Medicine

    Alzheimer Disease

    phase 1 small molecule active

    1 trial

  44. Dose dense re-challenge of high dose methotre...

    Pari Pharma GmbH

    Oncology: RELAPSED PRIMARY CNS LYMPHOMA

    phase 1 other active

    1 trial

  45. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  46. ENA-001

    BRIGHT MINDS BIOSCIENCES INC.

    Respiratory Depression

    phase 1 small molecule active

    1 trial

  47. Effect of NBI-921355 on corticospinal excitability in healthy participants

    NEUROCRINE BIOSCIENCES INC

    Epilepsy

    phase 1 other active

    1 trial

  48. First-in-Human Study of RO7812653

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)

    phase 1 other active

    1 trial

Frequently asked questions

How many neurology & cns Phase I programs exist?

138 programs match both the therapeutic area and stage filters in our published index.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.